Document Detail

Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
MedLine Citation:
PMID:  15205096     Owner:  NLM     Status:  MEDLINE    
The authors studied the long-term clinical and hematological response to hydroxyurea (HU) therapy in young patients, with either S/beta-thalassemia (beta(thal)) (8 patients) or SS (6 patients). All patients with S/beta(thal) responded well to treatment. Longitudinal evaluation of Hb, HbF, and MCV showed a significant increase compared to baseline levels, but the pattern of HbF changes varied among patients. Changes in HbF and Hb correlated well with baseline HbF. Favorable clinical responses, as documented by decline in hospitalization days for vasoocclusive crisis and transfused units of packed red blood cells, were also noted. During treatment, 1 patient was diagnosed with Hodgkin's lymphoma and 2 patients developed bilateral avascular necrosis of the femoral head. HU seems to be effective in a high proportion of young patients with sickle cell disease and in particular with S/beta(thal), but cannot eliminate occurrence of serious adverse events.
Antonis Kattamis; Evangelia Lagona; Irini Orfanou; Fotini Psichou; Vasilis Ladis; Emmanuel Kanavakis; Anna Metaxotou-Mavrommati; Christos Kattamis
Related Documents :
17298576 - Which patients are more likely to benefit from postoperative shed blood salvage after u...
21690596 - Assessment of thiopurine s-methyltransferase activity in patients prescribed thiopurine...
18194386 - Mannose-binding lectin is involved in multiple organ dysfunction syndrome after cardiac...
2240386 - Hypothermia and acidosis worsen coagulopathy in the patient requiring massive transfusion.
25217436 - Potential roles of vaptans in heart failure: experience from clinical trials and consid...
21219376 - The application of digital pulse amplitude tonometry to the diagnostic investigation of...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pediatric hematology and oncology     Volume:  21     ISSN:  0888-0018     ISO Abbreviation:  Pediatr Hematol Oncol     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-06-18     Completed Date:  2005-03-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8700164     Medline TA:  Pediatr Hematol Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  335-42     Citation Subset:  IM    
First Department of Pediatrics, University of Athens School of Medicine, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Sickle Cell / complications*,  drug therapy*
Erythrocyte Indices
Erythrocyte Transfusion
Fetal Hemoglobin / analysis
Hematologic Tests
Hemoglobins / analysis
Hydroxyurea / administration & dosage*
Length of Stay
Longitudinal Studies
Thalassemia / drug therapy
Treatment Outcome
Reg. No./Substance:
0/Hemoglobins; 127-07-1/Hydroxyurea; 9034-63-3/Fetal Hemoglobin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Increased fetal iron load in rhesus hemolytic disease.
Next Document:  Metamizole sodium-induced severe aplastic anemia and its recovery with a short-course steroid therap...